Zavegepant
Evidence-based neurology checklist on zavegepant: Pharmacology Zavegepant is a third‐generation small molecule CGRP receptor antagonist It has a rapid onset of action It has no cardiovascular precautions like the triptans It does not cause hepatotoxicity Dose Adverse effects
Pharmacology
- Zavegepant is a third‐generation small molecule CGRP receptor antagonist
- It has a rapid onset of action
- It has no cardiovascular precautions like the triptans
- It does not cause hepatotoxicity
Dose
Adverse effects
References
- Dhillon S. Zavegepant: first approval. Drugs 2023; 83:825-831.
- Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol 2023; 22:209-217.
- Croop R, Madonia J, Stock DA, et al. Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache 2022; 62:1153-1163.
